Abbott's Narrow Economic Moat Rests on a Solid Product Portfolio

While the pandemic caused some of Abbott's segments to balloon (diagnostics) and others to fall short (medical devices), conditions have largely normalized and Abbott's prospects will again rely heavily on its ability to consistently introduce innovative products. On margins, the company has made progress over the past 10 years but still lags key rivals on profitability measures despite competing in businesses that are characterized by attractive margins.